Alnylam advances Tuschl II patent estate through the USPTO Alnylam Pharmaceuticals.

These allowed claims are the 1st to emerge from the U newly.S. Prosecution of the Tuschl II patent series that include composition of matter for siRNA, the molecules that mediate RNAi. The Tuschl II patent family is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Max Planck Advancement GmbH, the licensing agent for the Max Planck Society.D., Senior Vice President, Chief Business Officer at Alnylam. ‘We think that our unparalleled intellectual home estate will safeguard the innovative medicines we advance to the market within our 'Alnylam 5×15' product technique.‘I don’t like to tell people ‘don’t consume this, don’t consume that,’ because it doesn’t work. People get frustrated.’ He would encourage people to modify their diet plan rather. For example, he suggests not having bacon or ham every full day for breakfast, but limiting it to once or twice a full week. ‘It’s probably best to lower it out, but I tend to be realistic, so I try to get people to decrease,’ he said.

Alexza Pharmaceuticals to meet up with FDA to discuss CRL regarding its NDA for AZ-004 Alexza Pharmaceuticals, Inc. announced today that the business has planned an End-of Review meeting with the U.S. Food and Drug Administration in December to discuss the entire Response Letter regarding the Company’s New Drug Software for AZ-004 .